Danish Pharmacovigilance Update, 16 February 2012

05 March 2012

In this issue of Danish Pharmacovigilance Update:

  • Risk of overdose with methotrexate in the treatment of rheumatoid arthritis and psoriasis (front page)
  • Gilenya (fingolimod) – intensified monitoring of heart rate and blood pressure after first dose (front page)
  • Newest data on the safety of methylphenidate (Ritalin etc.) in ADHD therapy (pp 2-3)
  • Risk of thromboembolism or death after discontinuation of anticoagulant therapy in patients with atrial fibrillation (pp 4-5)
  • Risk of venous thromboembolism from the use of 4th generation contraceptive pills (Yasmin® etc.) (p 6)
  • New report from the Danish Medicines Agency about the use of contraceptive pills and risk of thrombosis (pp 6-7)
  • Gilenya and macular oedema (p 7)
  • Haemorrhagic disease in a newborn whose mother was treated with valproate during pregnancy (p 8)
  • Study of the linkage between urine-derived fertility products and Creutzfeldt-Jakob (p 9)
  • The Danish Medicines Agency has drawn up a new report on pregnancy and adverse reactions from antidepressants (p 10)
  • New mobile app for checking medicines (p 10)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.